🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

342 results for “Novartis Pharmaceuticals” Clear

  1. OAV101

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 gene therapy completed

    1 trial

  2. OAV101B, Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  3. OCRELIZUMAB, LOU064, OCRELIZUMAB

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  4. OFC Infusion

    Novartis Pharmaceuticals

    Leukaemia, Lymphocytic, Chronic

    phase 3 small molecule completed

    1 trial

  5. Ofatumumab

    Novartis Pharmaceuticals

    Leukaemia, Lymphocytic, Chronic

    phase 3 mab terminated

    1 trial

  6. PACLITAXEL, ALPELISIB, DOXORUBICIN HYDROCHLORIDE, OLAPARIB, ALPELISIB, OLAPARIB

    Novartis Pharmaceuticals

    Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation

    phase 3 small molecule active

    1 trial

  7. PREDNISONE, Placebo to AIN457 150mg/1mL solution for injection in pre-filled syringe, SECUKINUMAB, PREDNISONE, Placebo to Prednisone 1 mg, 2.5mg, 5mg, 20mg hard gelatin capsule with tablet content, PREDNISONE, PREDNISONE, SECUKINUMAB, Placebo to AIN457 300mg/2mL solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Giant cell arteritis (GCA)

    phase 3 small molecule active

    1 trial

  8. Panobinostat

    Novartis Pharmaceuticals

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  9. Pelacarsen

    Novartis Pharmaceuticals

    Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial

  10. Placebo

    Novartis Pharmaceuticals

    IC-MPGN

    phase 3 small molecule active

    1 trial

  11. Placebo

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 mab completed

    1 trial

  12. Placebo - Film coated tablet for oral use, atrasentan

    Novartis Pharmaceuticals

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  13. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023 200 mg), IPTACOPAN

    Novartis Pharmaceuticals

    IgA Nephropathy

    phase 3 small molecule active

    1 trial

  14. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023), IPTACOPAN

    Novartis Pharmaceuticals

    generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  15. Placebo 0 mg hard gelatin capsule size 1, (placebo to lnp023 100 mg), Placebo 0 mg hard gelatin capsule size 0, (placebo to lnp023 200 mg), IPTACOPAN HYDROCHLORIDE, IPTACOPAN

    Novartis Pharmaceuticals

    complement 3 glomerulopathy

    phase 3 small molecule active

    1 trial

  16. Placebo 0 mg/1 mL Solution for infusion/injection, VAY736

    Novartis Pharmaceuticals

    Autoimmune hepatitis

    phase 3 small molecule active

    1 trial

  17. Placebo to AIN457 150 mg/ 1 mL Solution for injection in pre-filled syringe. This placebo is an additional/ alternative placebo to placebo to Xolair® (Omalizumab) to ensure continuous supply in the clinical trial. For more details please refer to Note to Assessor located in the “Placebo to AIN457” product shell., OMALIZUMAB , -, Placebo to Xolair® (Omalizumab) 150 mg/ml solution for injection in pre-filled syringe, LOU064, Placebo to Remibrutinib (LOU064) 25 mg film-coated tablet, -

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  18. Placebo to AIN457 300 mg/2 mL Solution for injection in pre-filled syringe, Cosentyx 300 mg solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Giant Cell Arteritis

    phase 3 small molecule active

    1 trial

  19. Placebo to AIN457 300mg/2mL Solution for injection in pre-filled syringe, SECUKINUMAB

    Novartis Pharmaceuticals

    Hidradenitis suppurativa

    phase 3 small molecule active

    1 trial

  20. Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, LOU064, CLINDAMYCIN , LOU064, -

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  21. Placebo to Remibrutinib (LOU064) 00 mg film-coated tablet, LOU064

    Novartis Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  22. Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, LOU064, LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  23. Placebo to Remibrutinib (LOU064) film-coated tablets, LOU064

    Novartis Pharmaceuticals

    Secondary progressive multiple sclerosis

    phase 3 small molecule active

    1 trial

  24. Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230

    Novartis Pharmaceuticals

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources